

HIV-1 vaccine development: Pinning down a moving target

12 November 2012

HIV-1 is a genetically diverse collection of viruses, making it a moving target in vaccine development.

In a study published in the [Journal of Clinical Investigation](#), researchers led by Brad Jones at the University of Toronto investigated the feasibility of eliminating HIV-infected cells by targeting cellular immune responses against a human endogenous retrovirus (HERV).

HERVs are the DNA remnants of ancient infectious retroviruses that became part of the germ line cells of our ancestors.

Jones and colleagues found that [HIV infection](#) stimulated the expression of HERV proteins, effectively tagging HIV-infected cells.

[Immune cells](#) targeted to these proteins specifically eliminated cells infected with several different strains of HIV in vitro. This study suggests that HERV-targeted immune responses should be considered in the development of HIV vaccines.

More information: HERV-K-targeted T-cells eliminate diverse HIV-1/2 and SIV primary isolates, *Journal of Clinical Investigation*, 2012.

Provided by Journal of Clinical Investigation

APA citation: HIV-1 vaccine development: Pinning down a moving target (2012, November 12) retrieved 11 June 2021 from <https://medicalxpress.com/news/2012-11-hiv-vaccine-pinning.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.